Intravenous Immune Globulin in Amyopathic Dermatomyositis - Report of Two Cases and Review of the Literature

Amyopathic dermatomyositis (ADM) is a rare subtype of dermatomyositis which is often recalcitrant to immune suppressing treatments. Intravenous immunoglobulin (IVIG) has been used in the treatment of refractory dermatomyositis. We present two patients with severe ADM, who were treated with IVIG at 2 g/kg every four weeks. Both patients had a successful response and were able to taper the dosage of prednisone. We present both cases in describing IVIG as a rescue and maintenance steroid-sparing agent in the treatment of severe refractory ADM. We also review the treatment of refractory ADM with IVIg in the English literature.

• Publication year

  2015

• Venue

  Open Rheumatology Journal

• Publication date

  2015-11-04

• Fields of study

  Medicine

• Identifiers
  DOI 10.2174/1874312901409010077PMID 26668670PMCID 4676053
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Clinical efficacy of intravenous immunoglobulins for the treatment of dermatomyositis skin lesions without muscle disease

  2014cited by this paper
• Intravenous immunoglobulin for refractory cutaneous dermatomyositis: a retrospective analysis from an academic medical center.

  2013cited by this paper
• A Novel Dermato-Pulmonary Syndrome Associated With MDA-5 Antibodies: Report of 2 Cases and Review of the Literature

  2012cited by this paper
• Intravenous immune globulin in autoimmune and inflammatory diseases.

  2012cited by this paper
• Pathogenic aspects of dermatomyositis, polymyositis and overlap myositis.

  2011cited by this paper
• Intravenous Immunoglobulin Therapy for Refractory Interstitial Lung Disease Associated with Polymyositis/Dermatomyositis

  2009influential reference
• Calcinosis cutis associated with amyopathic dermatomyositis: response to intravenous immunoglobulin.

  2009cited by this paper
• Dermatomyositis.

  2006cited by this paper
• An unusual presentation of amyopathic dermatomyositis associated with fatal interstitial lung disease.

  2006cited by this paper
• Acute Renal Failure and Intravenous Immune Globulin: Occurs with Sucrose-Stabilized, but Not with D-Sorbitol–Stabilized, Formulation

  2004cited by this paper
• Intractable skin necrosis and interstitial pneumonia in amyopathic dermatomyositis, successfully treated with cyclosporin A.

  2003cited by this paper
• Polymyositis and dermatomyositis

  2002cited by this paper
• Dermatomyositis.

  2000cited by this paper
• A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis.

  1993cited by this paper

• Amyopathic Dermatomyositis Presenting With Oral Mucocutaneous Lesion and No Muscle Involvement in an Elderly Woman: A Mimicry of Fungal Infection and Eczema

  2025influential citation
• Rapidly progressive interstitial lung disease due to anti-melanoma differentiation associated protein-5 requiring a bilateral lung transplant, and complicated by kennel cough

  2019cites this paper
• Recalcitrant ulcers associated with anti‐small ubiquitin‐like modifier activating enzyme‐positive dermatomyositis treated with surgery followed by intravenous immunoglobulin

  2018influential citation
• Intravenous immunoglobulins for treatment of connective tissue diseases in dermatology

  2018cites this paper
• Consenso Mexicano para la prescripción de inmunoglobulina G como tratamiento de reemplazo e inmunomodulación

  2018cites this paper
• Dermatología e inmunoglobulinas. ¿A quién y cómo administrarlas?

  2018cites this paper
• Dermatology and Immunoglobulin Therapy: Who to Treat and How to Administer Immunoglobulins.

  2018cites this paper
• Intravenous immunoglobulins in dermatology. Part 2: clinical indications and outcomes

  2018cites this paper
• Intravenous immunoglobulin: a biological corticosteroid-sparing agent in some autoimmune conditions

  2017cites this paper
• The skin in autoimmune diseases-Unmet needs.

  2016cites this paper